Impact Factor 2017: 1.634 (@Clarivate Analytics)
5-Year Impact Factor: 1.677 (@Clarivate Analytics)
  • Users Online: 645
  • Print this page
  • Email this page


 
 
Table of Contents
ORIGINAL ARTICLE
Year : 2018  |  Volume : 11  |  Issue : 12  |  Page : 688-692

Can miRNA712_3p be a promising biomarker for early diagnosis of toxoplasmosis?


1 Medical Parasitology Department, Faculty of Medicine, Alexandria University, Egypt
2 Medical Biochemistry Department, Faculty of Medicine, Alexandria University, Egypt
3 Pharmaceutical Chemistry, Faculty of Pharmacy and Drug Manufacturing, Pharos University in Alexandria, Alexandria, Egypt

Date of Submission05-Jul-2018
Date of Decision10-Dec-2018
Date of Acceptance19-Dec-2018
Date of Web Publication26-Dec-2018

Correspondence Address:
Nermine Mogahed Fawzy Hussein Mogahed
Medical Parasitology Department, Faculty of Medicine, Alexandria University
Egypt
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/1995-7645.248341

Get Permissions

  Abstract 

Objective: To assess the role of miRNA712_3p as a specific biomarker in early detection of toxoplasmosis in plasma of mice acutely infected with Toxoplasma gondii. Methods: Real-time PCR was used to measure the level of miRNA712_3p in plasma of infected mice. Immune-competent and immune-suppressed mice were examined, three and five days post-infection. Results: Results revealed significant up-regulation of plasma miRNA712_3p in both immune- competent and immune-compromised groups in comparison to the control non-infected group. Additionally, an increase in the level of miRNA712_3p was noticed correspondently in the parasite density detected in liver impression smears. Conclusions: miRNA712_3p can be used as a novel biomarker for the detection of Toxoplasma gondii infection in both immune-competent and immune-compromised host.

Keywords: Toxoplasma gondii, microRNAs, miRNA712_3p, Biomarker, Real-time PCR


How to cite this article:
Mogahed NF, Khedr SI, Ghazala RA, Masoud IM. Can miRNA712_3p be a promising biomarker for early diagnosis of toxoplasmosis?. Asian Pac J Trop Med 2018;11:688-92

How to cite this URL:
Mogahed NF, Khedr SI, Ghazala RA, Masoud IM. Can miRNA712_3p be a promising biomarker for early diagnosis of toxoplasmosis?. Asian Pac J Trop Med [serial online] 2018 [cited 2019 Jun 26];11:688-92. Available from: http://www.apjtm.org/text.asp?2018/11/12/688/248341


  1. Introduction Top


Toxoplasma gondii (T. gondii) is a highly successful obligatory intracellular protozoan. It is considered as one of the most prevalent parasites in the world with a wide range of hosts, including humans, causing toxoplasmosis. Nearly, one-third of the total human population is estimated to be seropositive[1]. People acquire the infection by three principal routes: foodborne, zoonotic from animals and congenitally from infected mother to her fetus. Organ transplant, blood transfusion and laboratory accidental infections are less common routes of human toxoplasmosis[2].

Toxoplasmosis has a wide spectrum of clinical picture ranging from life-threatening condition to long-term chronic asymptomatic infection. The life cycle of T. gondii is unique, as the parasite is capable of indefinite proliferation in its hosts with either sexual or asexual cycles. The sexual cycle occurs only in a feline host (cat), while the asexual cycle can occur in any warm-blooded animal. The parasite is capable of invading any nucleated cell within only 20 s, with preference to muscular and neural tissues in chronic condition[3].

Although infection in immune-competent adults is typically subclinical, it could persist for life. On the other hand, severe fatal consequences may occur in case of congenitally infected infants or in immune-compromised hosts[4],[5]. Treatment of pregnant women could reduce the incidence of sequels in congenitally infected infants[6]. Moreover, it is needless to mention that early detection of T. gondii infection can be considered as a key measure in reducing toxoplasmosis-related health problems in both immune-competent and immune-compromised individuals[7].

In spite of the presence of several commercially available serological tests for the diagnosis of acute toxoplasmosis, they have several disadvantages. As the parasite-specific antibodies may not be present during the early infection, false negative results particularly in immunosuppressed patients and in pregnant females can occur[8],[9]. Moreover, false-positive results in which IgM antibodies persist for a long period post infection may represent a great dilemma in congenital toxoplasmosis[10]. Therefore, an ideal method which does not depend on antibody detection is urgently needed[7].

Recently, it was found that circulating microRNAs (miRNAs) in the plasma or serum can be used in the diagnosis of cancers. Additionally, it was found that such circulating miRNAs could serve as biomarkers for the detection of infectious diseases as schistosomiasis and malaria[11],[12].

miRNAs are 18–22 nucleotide bases, endogenous regulatory factors that function to modulate cell differentiation and development[3]. They have the ability to regulate gene expression at the post-transcriptional level and are now considered as a key mechanism of gene regulation[13]. It was found that miRNAs released from a parasite are essential for cellular invasion, development and ability to respond to environmental and developmental signals. Moreover, they play an important role in modification of the host cellular environment for the parasite’s own benefit, fitness and immune evasion[13],[14],[15]. In 2013, Hirugnanam et al, concluded that toxoplasmosis may result in the initiation and progression of brain cancers through modifying the miRNA expression of human brain cells[16]. Several studies showed the significance of using plasma miRNA as biochemical markers for early detection of different types of human cancers, as colorectal, lung, pancreatic and prostatic cancers[17].

In contrary to usual RNA, miRNAs are stable enough to be detected in the plasma sample using quantitative time PCR (qRT- PCR)[18].

Researchers who tried to identify the T. gondii specific miRNAs found that miRNA712_3p is specifically expressed from the host cell during the process of host cell invasion by the parasite[7],[19].

In this study, real-time PCR was used to measure the level of miRNA712_3p in the plasma of immune-competent and immune-compromised mice acutely infected with 2 500 tachyzoites of the virulent RH T. gondii strain, at different post-infection durations.


  2. Materials and methods Top


2.1. Mice grouping and infection

Virulent RH HXGPRT (-) strain of T. gondii used in this study is routinely maintained in the laboratory of Medical Parasitology Department, Faculty of Medicine, Alexandria University, Egypt, which is cultivated by serial intraperitoneal passages of T. gondii tachyzoites into mice. A total of 36 male Swiss strain albino mice were divided equally into three main groups: I (normal, non-infected control group), II (immune-competent group) and III (immune-compromised group). Immune-suppression was induced by intraperitoneal injection of the anticancer drug, endoxan, in two doses (70 mg/kg each) one week apart[20]. Two days after the last dose of endoxan, mice were injected intraperitoneally with 2 500 tachyzoites of the virulent RH strain. Three and five days post infection mice from different groups were sacrificed by euthanasia using terminal anesthesia maneuver. The experimental design followed the guidelines of laboratory animal care, according to the Ethical Committee, Faculty of Medicine, Alexandria University, based on international regulations of animal care (IRB NO: 00007555-FWA NO: 00018699). Infection was confirmed by Giemsa staining of peritoneal fluid after mice sacrifice[8].

2.2. Plasma sample collection

Immune-competent and immune-compromised groups were subdivided into two equal subgroups. Two subgroups were sacrificed three days post infection ( IIa & III a), while the other subgroups were sacrificed five days post infection ( Π b & fflb). Sacrificed mice were exsanguinated, and blood was mixed with heparin for plasma separation. Blood samples were centrifuged at 1 200 g/min for 10 min, at room temperature, to remove the blood cells, followed by a second centrifugation at 12. 000 g/min for 10 min, at 4 °C to remove other cellular components. Plasma samples were then stored at 80 °C until further processing[7].

2.3. Parasite count

T. gondii tachyzoites were counted in impression smears from livers of the sacrificed mice of all subgroups, at different post-infection durations[8].

2.4. RNA isolation

Total plasma RNA was isolated using miRNeasy Mini Kit (QIAGEN), according to the manufacturer’s protocol. Briefly, synthetic cel-miR-39 was added to each sample as a spike-in control, then total RNA was purified from 400 μL of plasma sample. The miRNeasy Mini Kit contains phenol/guanidine-based lysis of samples and silica membrane-based purification of total RNA. Samples were homogenized in QIAzol lysis reagent. After addition of chloroform, the homogenate was separated into aqueous and organic phases by centrifugation. RNA partitions to the upper aqueous phase, while DNA partitions to the interphase and proteins to the lower organic phase or the interphase. The upper aqueous phase was extracted, and ethanol was added to provide appropriate binding conditions for all RNA molecules from 18 nucleotides (nt) upwards. The sample was then applied to the RNeasy mini spin column, where the total RNA binds to the membrane and phenol and other contaminants are efficiently washed away. High quality RNA is then eluted in RNase-free water. The concentration of total RNA samples from plasma was quantified by a Nanodrop 2000 (Nanodrop, USA). The range of the result was from 11.9 to 73.7 ng/μL[7].

2.5. Real-time quantitative reverse-transcription PCR (RT PCR)

The TaqMan® MicroRNA Reverse Transcription Kit supplied by Applied Biosystem was used for the reverse transcription reaction. The recommended reaction volume was 20 μL. The plate was prepared so ABI prism 7900 sequence detection system (Ambion, USA) could be used for amplification and detection. Differences in miRNA712_3p were normalized to cel-miR-39, determined with the ΔCt method, and reported as 2-ΔΔCt[7].

2.6. Statistical analysis

Quantitative data of the present work was analyzed, using F-test (ANOVA)and post hoc test (Scheffe) for pairwise comparison. P<0.05 was considered statistically significant. All statistical calculations were performed using IBM SPSS software package version 20.0.


  3. Results Top


The aim of the present study was to investigate whether infection by T. gondii can drive changes to murine miRNA plasma levels in both immune-competent and immune-compromised mice several days post infection, or not.

To test our hypothesis, miRNA712_3p level in plasma samples from infected mice were profiled, three and five days post infection in the four studied subgroups in comparison to the non-infected control group.

3.1. miRNA712_3p is up-regulated in mice infected with T. gondii

RT PCR results revealed that miR-712_3p level was significantly up-regulated in plasma samples of infected immune-competent subgroups (II a & IIb), at 26.1 & 54.0 folds, three and five days post infection respectively [Table 1]. A statistically significant difference was evident between the infected mice and the non-infected control group.
Table 1: Comparison between different studied subgroups according to level of miRNA712_3p levels in mice plasma sample.

Click here to view


At the same time, the immune-compromised subgroups (IIIa & III b) showed up-regulation of the specific miRNA level to 4.0 and 8.8 folds, three and five days post infection respectively. The difference between the immune-compromised subgroups was statistically significant [Table 1]. Moreover, the increase in the miRNA level in all studied subgroups was revealed to be statistically significant compared to the control non-infected mice.

3.2. Parasite count in liver impression smears

The parasites were counted, three and five days post-infection. Tachyzoites of RH-infected subgroups were observed intracellular and extracellular. The mean tachyzoite count in impression smears obtained from immune-competent subgroups (Π a) in the third-day post-infection was (0.783±0.343) tachyzoites/oil immersion field (OIF). The count showed 4.7 folds increase by the fifth-day post infection (3.667±2.059) tachyzoites/OIF, and the difference in parasite count was found to be statistically significant [Table 2].
Table 2: Comparison between different studied infected subgroups regarding Toxoplasma tachyzoites count in liver impression smears three and five days post infection.

Click here to view


As regards the immune-compromised subgroups (III a & III b), the mean tachyzoite count was (0.533±0.308) tachyzoites/OIF, three days post infection. Five days post-infection, the mean tachyzoite count showed an increase up to 1.9 folds. The difference in the mean count was found to be statistically significant, three and five days post infection [Table 2].


  4. Discussion Top


miRNAs are small RNA sequences that can regulate gene expression at the post-transcriptional level[21]. They can exert their action by targeting protein-encoding messenger RNAs (mRNA)[22]. Several studies reported their role in diverse biological aspects within the cell, including organism development, immune modulation, metabolism and cell death[23],[24],[25].

In recent years, it was evident that plasma miRNA can be used as a promising tool for diagnosis of several diseases[26],[27],[28]. In 2008, miRNA was used for the first time in tumor diagnosis[17]. In the same year, Lawrie et al. reported tumor associated miRNA as a non-invasive diagnostic tool of diffuse B-cell lymphoma[29]. Thereafter, it was used in diagnostic trials for other cancers[30].

In 2012, Wang et al. found an evidence for the differential expression of miRNAs in the two genetically distinct strains of T. gondii, RH virulent and Me 49 avirulent strain[3]. Among over 1 000 miRNAs investigated, miR-132 was the only one that was up-regulated more than 2 folds increase, by the three different T. gondii strains[31],[32]. In 2014, two different mature forms of T. gondii specific miR-712 were recorded, 712-5p and miR-712-3p. These miRNAs were reported to be specific for RH strain, but their role as a diagnostic marker for toxoplasmosis in immunosuppression was still unknown[7].

This study was carried out on plasma samples collected from mice previously infected with 2 500 tachyzoites of RH strain. The samples were processed and preserved under -80 °C till RNA extraction was carried out according to Aiso et al., who reported that freezing of the plasma sample recorded a better detection of miRNAs[33].

In the present work, detection of circulating miRNA712_3p in the plasma of T. gondii-infected mice was feasible. miRNA712_3p level significantly has been up-regulated in all infected subgroups II a, nb, IIIa & IIIb) in comparison to non-infected control group ( I ), with 54.0 folds increase in the immune-competent mice, five days post infection. This may be due to the ability of T. gondii to control host cell microenvironment. This control measure occurs through channelizing parasite proteins into the host cell cytoplasm through the parasitophorous vacuole. Some of the proteins are targeted to the host nucleus regulating gene expression at the post-transcriptional level, leading to transcription of regulatory microRNAs specific to these parasites[34].

Both miRNA 712_3p and T. gondii parasite activity are greatly influenced by the process of Ca2+ mobilization within the cell[35]. T. gondii depends on Ca2+ metabolism in both movement and invasion of the host cell[35]. This may be the main mechanism which can explain the high increase in the level of miRNA 712_3p in infected mice in direct association with the duration of infection, due to the increase in the number of moving, replicating and invasive parasites[35].

In agreement with our results, Jia et al. reported an up to 80.62 folds increase in the level of several miRNAs in plasma of mice, 72 h after intra peritoneal infection with 106 tachyzoites of RH strain compared to control non-infected mice[7]. The higher increase in the latter study could be attributed to the variation in the infective dose.

The fold increase in the plasma miRNAs level was significantly higher in immune-competent subgroup than in the immune-compromised one on the third and fifth days post infection respectively. This difference may be due to the impact of regulatory miRNA on the immune response, as they act as mediators for both innate and acquired immune responses[36]. In 2011, Tserel et al. reported the role of miRNAs on control of macrophage production and activation, noticing that macrophages are the main host cell needed by the parasite, and determining the multiplication power of the parasite within it. The authors reported the role of microRNAs in the regulation of eosinophilic recruitment in case of T. gondii induced eosinophilic meningitis[37]. Down-regulation of the main host cell recruitment reduces the multiplication power of the parasite leading to a reduction in the secreted proteins which in-turn stimulate the production of miRNAs, and so on. Talari et al., in 2017, reported that ectopic expression of miR-712 impaired the secretion of proinflammatory cytokines such as TNF-α, IL-6, and IFN-β, thus, decreasing recruitment of inflammatory cells and macrophages[38].

It is worth mentioning that, the parasite and the host cell have the ability to produce several regulatory miRNAs, and the end result of their battle will determine which one can predominate over the other[39].

The mean tachyzoite count in Giemsa stained liver impression smears was considered as an indicator for progression of infection. Therefore, in the present study, the tachyzoite load in the liver was studied to demonstrate the role of parasite multiplication on the variations in micRNA 712_3p level.

There was a statistically significant increase in the mean tachyzoite count in the studied infected subgroups sacrificed on the fifth day (3.667±2.059) tachyzoites/OIF, in comparison to the other subgroup, sacrificed on the third-day post infection (0.783±0.343) tachyzoites/ OIF. This result was in agreement with Mahmoud[40] who also used Giemsa stain impression smear as a parasitological parameter for drug efficacy; the mean tachyzoite count in the control subgroup infected with 2 500 tachyzoites was (6.27±2.67) tachyzoites/OIF on the seventh-day post infection denoting an increase in the parasite load with time[40]. In the present work, the increase in the mean tachyzoites count was found to be more evident in the immune-competent subgroup sacrificed on the fifth day in comparison to the immune-compromised subgroup sacrificed on the same day. The difference in parasite count between immune-competent and immune-compromised subgroups may be due to reduction in number of the main host cell, macrophages, induced by endoxan, hence, decreasing the multiplication power of the parasite. Therefore, it was noted that the increase in the level of miRNA was in association with the increase in the parasite density, as detected by liver impression smears.

The present work noted the significant up-regulation of T. gondii specific microRNA 713-3p in murine plasma samples, few days post infection, in both immune-competent and immune-compromised mice. Thus, it raises hope for opening a new scope for early diagnosis of acute toxoplasmosis.

Conflict of interest statement

We declare that we have no conflict of interests.

 
  References Top

1.
Wang ZD, Wang SC, Liu HH, Ma HY, Li ZY, Wei F, et al. Prevalence and burden of Toxoplasma gondii infection in HIV-infected people: A systematic review and meta-analysis. Lancet HIV 2017; 4(4): e177-e188.  Back to cited text no. 1
    
2.
Hide G. Role of vertical transmission of Toxoplasma gondii in prevalence of infection. Expert Rev Anti Infect Ther 2016; 14(3): 335-344.  Back to cited text no. 2
    
3.
Wang J, Liu X, Jia B, Lu H, Peng S, Piao X, et al. A comparative study of small RNAs in Toxoplasma gondii of distinct genotypes. Parasit Vectors 2012; 5: 186.  Back to cited text no. 3
    
4.
Flegr J. Schizophrenia and Toxoplasma gondii: An undervalued association? Expert Rev Anti Infect Ther 2015 ; 13(7): 817-820.  Back to cited text no. 4
    
5.
Kaparos N, Favrat B, D’Acremont V. Fever and lymphadenopathy: Acute toxoplasmosis in an immunocompetent patient. Rev Med Suisse 2014; 10(452): 2266-2268.  Back to cited text no. 5
    
6.
Shieh M, Didehdar M, Hajihossein R, Ahmadi F, Eslamirad Z. Toxoplasmosis: Seroprevalence in pregnant women, and serological and molecular screening in neonatal umbilical cord blood. Acta Trop 2017; 174: 38-44.  Back to cited text no. 6
    
7.
Jia B, Chang Z, Wei X, Lu H, Yin J, Jiang N, et al. Plasma microRNAs are promising novel biomarkers for the early detection of T. gondii infection. Parasit Vectors 2014; 7: 433.  Back to cited text no. 7
    
8.
Temsahy MM, El Kerdany EDH, Eissa MM, Shalaby T, Talaat IM, Mogahed NMFH. The effect of chitosan nanospheres on the immunogenicity of T. gondii lysate vaccine in mice. J Parasit Dis 2016; 40(3): 611-626.  Back to cited text no. 8
    
9.
Rajput R, Denniston AK, Murray PI. False negative Toxoplasma serology in an immunocompromised patient with PCR positive ocular toxoplasmosis. Ocul Immunol Inflamm 2017 ; 12: 1-3.  Back to cited text no. 9
    
10.
Paquet C, Yudin MH. Toxoplasmosis in pregnancy: Prevention, screening, and treatment. J Obstet Gynaecol Can 2013; 35(1): 78-81. .  Back to cited text no. 10
    
11.
Zhu L, Liu J, Cheng G. Role of microRNAs in Schistosomes and schistosomiasis. Front Cel l Infect Microbiol 2014; 4: 165.  Back to cited text no. 11
    
12.
Chamnanchanunt S, Fucharoen S, Umemura T. Circulating microRNAs in malaria infection: Bench to bedside. Malar J 2017; 16(1): 334.  Back to cited text no. 12
    
13.
Du T, Zamore PD. Beginning to understand microRNA function. Cell Res 2007; 17: 661– 663.  Back to cited text no. 13
    
14.
Bartel DP. MicroRNAs: Target recognition and regulatory functions. Cell 2009; 23: 136(2):215-233.  Back to cited text no. 14
    
15.
Lin W C, Li S C, Lin WC, Shin JW, Hu SN, Yu XM, et al. Identification of microRNA in the protist Trichomonas vaginalis. Genomics 2009; 93(5): 487–93.  Back to cited text no. 15
    
16.
Hirugnanam S, Rout N, Gnanasekar M. Possible role of T. gondii in brain cancer through modulation of host microRNAs. Infect Agent Cancer 2013; 8: 8.  Back to cited text no. 16
    
17.
Hayes J, Peruzzi PP, Lawler S. MicroRNAs in cancer: biomarkers, functions and therapy. Trends Mol Med 2014; 20(8): 460-469.  Back to cited text no. 17
    
18.
Cheng G. Circulating miRNAs: Roles in cancer diagnosis, prognosis, and therapy. Adv Drug Deliv Rev 2014; 81: 75-93.  Back to cited text no. 18
    
19.
Xu MJ, Zhou DH, Nisbet AJ, Huang SY, Fan YF, Zhu XQ. Characterization of mouse brain microRNAs after infection with cyst-forming T. gondii. Parasit Vectors 2013; 6: 1154.  Back to cited text no. 19
    
20.
Sherwood D, Angus KW, Snodgrass DR, Tzipori S. Experimental cryptosporidiosis in laboratory mice. Infect Immunol 1982; 38(2): 471-475.  Back to cited text no. 20
    
21.
Bartel DP. MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell 2004; 116(2): 281-297.  Back to cited text no. 21
    
22.
Han HX, Peng Y, Hong M, Zhang YH, Han DD, Liu DD, et al. MicroRNA expression profile in different tissues of BALB/c mice in the early phase of Schistosoma japonicum infection. Mol Biochem Parasitol 2013; 188(1): 1-9.  Back to cited text no. 22
    
23.
Catalanotto C, Cogoni C, Zardo G. MicroRNA in control of gene expression: An overview of nuclear functions. Int J Mol Sci 2016; 17(10): 1712.  Back to cited text no. 23
    
24.
Mohr AM, Mott JL. Overview of microRNA biology. Semin Liver Dis 2015; 35(1): 3-11.  Back to cited text no. 24
    
25.
Miska EA. How microRNAs control cell division, differentiation and death. Curr Opin Genet Dev 2005;15(5): 563-568.  Back to cited text no. 25
    
26.
Ali T, Mushtaq I, Maryam S, Farhan A, Saba K, Jan MI, et al. Interplay of N- acetyl cysteine and melatonin in regulating oxidative stress-induced cardiac hypertrophic factors and microRNAs. Arch Biochem Biophys 2019; 661:56-65.  Back to cited text no. 26
    
27.
Amacher DE, Adler R, Herath A, Townsend RR. Use of proteomic methods to identify serum biomarkers associated with rat liver toxicity or hypertrophy. Clin Chem 2005; 51(10): 1796–1803.  Back to cited text no. 27
    
28.
Rezk NA, Sabbah NA, Saad MS. Role of MicroRNA 126 in screening, diagnosis, and prognosis of diabetic patients in Egypt. IUBMB Life 2016; 68(6): 452-458.  Back to cited text no. 28
    
29.
Lawrie CH, Gal S, Dunlop HM, Pushkaran B, Liggins AP, Pulford K, et al. Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol 2008; 141(5): 672–675.  Back to cited text no. 29
    
30.
Peng Q, Zhang X, Min M, Zou L, Shen P, Zhu Y. The clinical role of microRNA-21 as a promising biomarker in the diagnosis and prognosis of colorectal cancer: a systematic review and meta-analysis. Oncotarget 2017; 8(27): 44893-44909.  Back to cited text no. 30
    
31.
Xiao J, Li Y, Prandovszky E, Karuppagounder SS, Talbot CC, Dawson VL, et al. MicroRNA-132 dysregulation in T. gondii infection has implications for dopamine signaling pathway. Neuroscienc 2014; 268: 128-138.  Back to cited text no. 31
    
32.
Li Y, Kannan G, Pletnikov MV, Yolken RH, Xiao J. Chronic infection of Toxoplasma gondii downregulates miR-132 expression in multiple brain regions in a sex-dependent manner. Parasitology 2015; 142(4): 623-632.  Back to cited text no. 32
    
33.
Aiso T, Takigami S, Yamaki A, Ohnishi H. Degradation of serum microRNAs during transient storage of serum samples at 4 °C. Ann Clin Biochem 2018; 55(1): 178-180.  Back to cited text no. 33
    
34.
Thirugnanam S, Rout N, Gnanasekar M. Possible role of T. gondii in brain cancer through modulation of host microRNAs. Infect Agent Cancer 2013; 8(1): 8.  Back to cited text no. 34
    
35.
Nagamune K, Moreno SN, Chini EN, Sibley LD. Calcium regulation and signaling in apicomplexan parasites. Subcell Biochem 2008; 47: 70-81.  Back to cited text no. 35
    
36.
Sonkoly E, Stahle M, Pivarcsi A. MicroRNAs and immunity: Novel players in the regulation of normal immune function and inflammation. Semin Cancer Biol 2008; 18 (2): 131-140.  Back to cited text no. 36
    
37.
Tserel L, Runnel T, Kisand K, Pihlap M, Bakhoff L, Kolde R, et al. MicroRNA expression profiles of human blood monocyte-derived dendritic cells and macrophages reveal miR-511 as putative positive regulator of Toll-like receptor 4. J Biol Chem 2011; 286(30): 26487–26495.  Back to cited text no. 37
    
38.
Talari M, Nayak TK, Kain V, Babu PP, Misra P, Parsa KV. MicroRNA- 712 restrains macrophage pro-inflammatory responses by targeting LRRK2 leading to restoration of insulin stimulated glucose uptake by myoblasts. Mol Immunol 2017; 82: 1-9.  Back to cited text no. 38
    
39.
Dale JW and Schantz MV. From genes to genomes genes concepts and applications of DNA technology. 2nd ed. Canada: John Wiley & sons Ltd.; 2007, p. 313-332.  Back to cited text no. 39
    
40.
Mahmoud YE. Effect of nitazoxanide and spiramycin co-administered with metronidazole in a murine model of acute toxoplasmosis. MS thesis, Medical Research Institute, Alexandria University, Egypt. 2017.  Back to cited text no. 40
    



 
 
    Tables

  [Table 1], [Table 2]



 

Top
 
  Search
 
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

  2. Materials and...
  In this article
Abstract
1. Introduction
3. Results
4. Discussion
References
Article Tables

 Article Access Statistics
    Viewed333    
    Printed8    
    Emailed0    
    PDF Downloaded60    
    Comments [Add]    

Recommend this journal